Darinaparsin (ZIO-101) enhances the sensitivity of small-cell lung cancer to PARP inhibitors
文献类型：期刊论文
| 作者 | Cao, Guo-Zhen1,4,5; Ma, Li-Ying1,4,5; Zhang, Zong-Hui1,3; Wang, Xiao-Lin5 ; Hua, Jing-Han1,4,5; Zhang, Jia-Hui1,4,5; Lv, Yang1,4,5; Zhang, Shao-Bo1,3; Ou, Jian2; Lin, Wen-Chu1,4,5
|
| 刊名 | ACTA PHARMACOLOGICA SINICA
 |
| 出版日期 | 2022-10-17 |
| 关键词 | small-cell lung cancer H3 3 PARP1 PARP inhibitor darinaparsin combination treatment |
| ISSN号 | 1671-4083 |
| DOI | 10.1038/s41401-022-00994-4 |
| 通讯作者 | Lin, Wen-Chu(wenchu@hmfl.ac.cn) |
| 英文摘要 | Small-cell lung cancer (SCLC) is an aggressive high-grade neuroendocrine carcinoma of the lung associated with early metastasis and an exceptionally poor prognosis. Little progress has been made in developing efficacious targeted therapy for this recalcitrant disease. Herein, we showed that H3.3, encoded by two genes (H3F3A and H3F3B), was prominently overexpressed in SCLC. Darinaparsin (ZIO-101), a derivative of arsenic trioxide, dose- and time-dependently inhibited the viability of SCLC cells in an H3.3-dependent manner. More importantly, ZIO-101 treatment resulted in substantial accumulation of H3.3 and PARP1 besides induction of G(2)/M cell cycle arrest and apoptosis in SCLC cells. Through integrative analysis of the RNA-seq data from Cancer Cell Line Encyclopedia dataset, JNCI and Genomics of Drug Sensitivity in Cancer 2 datasets, we found that H3F3A expression was negatively correlated with the IC50 values of PARP inhibitors (PARPi). Furthermore, co-targeting H3.3 and PARP1 by ZIO-101 and BMN673/olaparib achieved synergistic growth inhibition against SCLC in vitro and in vivo. In conclusion, it is feasible to target H3.3 by ZIO-101 to potentiate the response rate of PARPi in SCLC patients. |
| WOS关键词 | HISTONE VARIANT H3.3 ; TUMOR ; MUTATIONS ; DISEASE ; TARGETS |
| 资助项目 | National Natural Science Foundation of China (China)[81972191] ; National Natural Science Foundation of China (China)[81672647] ; High Magnetic Field Laboratory of Anhui Province |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000869326100002 |
| 出版者 | NATURE PUBL GROUP |
| 资助机构 | National Natural Science Foundation of China (China) ; High Magnetic Field Laboratory of Anhui Province |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/129470]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Lin, Wen-Chu |
| 作者单位 | 1.Chinese Acad Sci, Hefei Inst Phys Sci, High Magnet Field Lab, Hefei 230031, Peoples R China 2.Nanjing Med Univ, Suzhou Municipal Hosp, Ctr Reprod & Genet, Affiliated Suzhou Hosp, Suzhou 215002, Peoples R China 3.Anhui Med Univ, Sch Basic Med, Hefei 230032, Peoples R China 4.Chinese Acad Sci, Hefei Inst Phys Sci, Key Lab High Magnet Field & Ion Beam Phys Biol, Hefei 230031, Peoples R China 5.Univ Sci & Technol China, Hefei 230036, Peoples R China |
| 推荐引用方式 GB/T 7714 | Cao, Guo-Zhen,Ma, Li-Ying,Zhang, Zong-Hui,et al. Darinaparsin (ZIO-101) enhances the sensitivity of small-cell lung cancer to PARP inhibitors[J]. ACTA PHARMACOLOGICA SINICA,2022. |
| APA | Cao, Guo-Zhen.,Ma, Li-Ying.,Zhang, Zong-Hui.,Wang, Xiao-Lin.,Hua, Jing-Han.,...&Lin, Wen-Chu.(2022).Darinaparsin (ZIO-101) enhances the sensitivity of small-cell lung cancer to PARP inhibitors.ACTA PHARMACOLOGICA SINICA. |
| MLA | Cao, Guo-Zhen,et al."Darinaparsin (ZIO-101) enhances the sensitivity of small-cell lung cancer to PARP inhibitors".ACTA PHARMACOLOGICA SINICA (2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。